Since 2005, anti-VEGF drug injections have proved effective for treatment of neovascularization* secondary to age-related macular degeneration (AMD) and diabetic macular edema (DME). Several newer anti-VEGF therapies are also under study, including PAN-90806, OPT-302, ICON-1, RGX-314, and RTH258. All of these are described and sourced on this site.
Recently, scientists have researched a possible counterpart to VEGF called angiopoietin2 (Ang2). It appears that a second substance produced by the body can, like VEGF, also lead to uncontrolled neovascularization in patients with compromised autoimmune systems. The researchers are hoping that, by inhibiting the body’s production of that substance, in combination with anti-VEGF treatment, the retinal blood vessels can be further stabilized.
Two “anti-Ang2” drugs are being studied for that purpose. RG7716 is being tested in combination with Lucentis (Genentech), and nesvacumab (REGN910) is being tested in combination with Eylea (Regeneron). Both drugs have demonstrated safety and tolerability in pre-clinical and Phase 1 trials and are ready to move forward.
*Growth of new, fragile blood vessels which may leak beneath the retina.